vs
Enact Holdings, Inc.（ACT）与Ascendis Pharma A/S（ASND）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Ascendis Pharma A/S的1.2倍（$312.7M vs $267.3M），Ascendis Pharma A/S同比增速更快（42.3% vs 3.6%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
ACT vs ASND — 直观对比
营收规模更大
ACT
是对方的1.2倍
$267.3M
营收增速更快
ASND
高出38.7%
3.6%
两年增速更快
ASND
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $267.3M |
| 净利润 | — | — |
| 毛利率 | — | 90.5% |
| 营业利润率 | 71.3% | — |
| 净利率 | — | — |
| 营收同比 | 3.6% | 42.3% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $1.23 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTASND
| Q4 25 | $312.7M | $267.3M | ||
| Q3 25 | $311.5M | $230.7M | ||
| Q2 25 | $304.9M | $170.7M | ||
| Q1 25 | $306.8M | $109.0M | ||
| Q4 24 | $301.8M | $187.8M | ||
| Q3 24 | $309.6M | $62.5M | ||
| Q2 24 | $298.8M | $38.9M | ||
| Q1 24 | $291.6M | $103.6M |
净利润ACTASND
| Q4 25 | — | — | ||
| Q3 25 | — | $-65.9M | ||
| Q2 25 | — | $-42.0M | ||
| Q1 25 | — | $-102.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-107.1M | ||
| Q2 24 | — | $-118.1M | ||
| Q1 24 | — | $-141.5M |
毛利率ACTASND
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 89.5% | ||
| Q2 25 | — | 80.1% | ||
| Q1 25 | — | 82.6% | ||
| Q4 24 | — | 91.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 68.2% | ||
| Q1 24 | — | 92.1% |
营业利润率ACTASND
| Q4 25 | 71.3% | — | ||
| Q3 25 | 67.4% | 5.1% | ||
| Q2 25 | 70.4% | -33.5% | ||
| Q1 25 | 68.9% | -103.2% | ||
| Q4 24 | 68.9% | — | ||
| Q3 24 | 74.1% | -167.3% | ||
| Q2 24 | 78.6% | -370.2% | ||
| Q1 24 | 70.6% | -51.2% |
净利率ACTASND
| Q4 25 | — | — | ||
| Q3 25 | — | -28.5% | ||
| Q2 25 | — | -24.6% | ||
| Q1 25 | — | -93.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -171.5% | ||
| Q2 24 | — | -303.9% | ||
| Q1 24 | — | -136.6% |
每股收益（稀释后）ACTASND
| Q4 25 | $1.23 | — | ||
| Q3 25 | $1.10 | — | ||
| Q2 25 | $1.11 | — | ||
| Q1 25 | $1.08 | — | ||
| Q4 24 | $1.05 | — | ||
| Q3 24 | $1.15 | — | ||
| Q2 24 | $1.16 | — | ||
| Q1 24 | $1.01 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $665.3M |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $-175.8M |
| 总资产 | $6.9B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTASND
| Q4 25 | $582.5M | $665.3M | ||
| Q3 25 | $545.6M | $582.2M | ||
| Q2 25 | $616.0M | $533.6M | ||
| Q1 25 | $639.0M | $559.4M | ||
| Q4 24 | $602.8M | $604.3M | ||
| Q3 24 | $674.9M | $675.6M | ||
| Q2 24 | $711.3M | $279.4M | ||
| Q1 24 | $624.3M | $345.9M |
总债务ACTASND
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
股东权益ACTASND
| Q4 25 | $5.4B | $-175.8M | ||
| Q3 25 | $5.3B | $-188.0M | ||
| Q2 25 | $5.2B | $-202.6M | ||
| Q1 25 | $5.1B | $-205.0M | ||
| Q4 24 | $5.0B | $-114.2M | ||
| Q3 24 | $5.0B | $-105.1M | ||
| Q2 24 | $4.8B | $-346.8M | ||
| Q1 24 | $4.7B | $-257.2M |
总资产ACTASND
| Q4 25 | $6.9B | $1.4B | ||
| Q3 25 | $6.9B | $1.2B | ||
| Q2 25 | $6.8B | $1.2B | ||
| Q1 25 | $6.7B | $1.1B | ||
| Q4 24 | $6.5B | $1.3B | ||
| Q3 24 | $6.6B | $1.2B | ||
| Q2 24 | $6.3B | $819.0M | ||
| Q1 24 | $6.3B | $866.7M |
负债/权益比ACTASND
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $58.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACTASND
| Q4 25 | $724.5M | $58.2M | ||
| Q3 25 | $192.0M | — | ||
| Q2 25 | $119.5M | — | ||
| Q1 25 | $226.7M | $-15.5M | ||
| Q4 24 | $686.3M | $-330.7M | ||
| Q3 24 | $188.1M | — | ||
| Q2 24 | $144.7M | — | ||
| Q1 24 | $187.3M | $-109.7M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
